Brought to you by 
Merck KGAA forms IBS spin-out Tioga Pharmaceuticals
19 Sep 2005
Executive Summary
Merck KGAA has spun out Tioga Pharmaceuticals, a new company formed to further develop Merck's asimadoline for irritable bowel syndrome (IBS). Tioga raised an undisclosed amount in its Series A financing (including an investment by Forward Ventures), and is already planning to raise additional funds.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
- Spin-Off
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck KGAA forms IBS spin-out Tioga Pharmaceuticals
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice